Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib in Advanced Non-Small Cell Lung Cancer
NCT00174369Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirdametinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Activity of PD-0325901. Started Nov 2005; status: terminated.
02
Drugs
mirdametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00174369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174369.